Altimmune (ALT) Form 3: CMO Reports No Holdings on 10/01/2025

Altimmune, Inc. (ALT) filed a Form 3 reporting that Christophe Arbet-Engels, serving as Chief Medical Officer and an officer/director, has no securities beneficially owned in the company as of the event date 10/01/2025.

Rhea-AI Filing Summary

Altimmune, Inc. (ALT) filed a Form 3 reporting that Christophe Arbet-Engels, serving as Chief Medical Officer and an officer/director, has no securities beneficially owned in the company as of the event date 10/01/2025. The filing notes a Power of Attorney (Exhibit 24) and is signed by Gregory Weaver, as Attorney-in-Fact on 10/03/2025. This is an initial ownership statement required by Section 16; it discloses the reporting person’s relationship to the issuer and that no equity or derivative holdings are reported on the form.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Altimmune's Form 3 by Christophe Arbet-Engels report?

The Form 3 states that Christophe Arbet-Engels, the Chief Medical Officer, beneficially owns no securities of Altimmune as of 10/01/2025.

What is the reporting relationship disclosed on the Form 3 for ALT?

The filing identifies the reporting person as a Director and an Officer with the title Chief Medical Officer.

Was the Form 3 signed and by whom?

Yes. The Form 3 includes a signature block showing Gregory Weaver, as Attorney-in-Fact, signed on 10/03/2025.

Does the filing include any securities or derivative holdings?

No. The filing explicitly states "No securities are beneficially owned."

Does the Form 3 reference any exhibits?

Yes. The filing references Exhibit 24, which is a Power of Attorney.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:21 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Arbet-Engels Christophe

(Last) (First) (Middle)

C/O ALTIMMUNE, INC.

910 CLOPPER ROAD, SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/01/2025

3. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Gregory Weaver, as Attorney-in-Fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.